Clinical Trials Logo

Anal Intraepithelial Neoplasia clinical trials

View clinical trials related to Anal Intraepithelial Neoplasia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03603808 Active, not recruiting - Clinical trials for Anal Intraepithelial Neoplasia

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Start date: September 21, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions.

NCT ID: NCT02059499 Active, not recruiting - HIV Infection Clinical Trials

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Start date: December 28, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions.